<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260629070006N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-08-25</date_registration>
      <primary_sponsor>Razi University, Kermanshah</primary_sponsor>
      <public_title>The effects of transcranial electrical brain stimulation on pain, balance, and motor function in female students with anterior knee pain</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of The Effects of Single-Site and Concurrent Transcranial Direct Current Stimulation (M1, DLPFC) on Pain Intensity, Balance, Motor Function and Quadriceps Muscle Strength in Female Students with Patellofemoral Pain Syndrome</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-08-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>42</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/91872</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Eligible participants were randomly allocated using simple randomization to three groups of 14 participants each: Experimental Group 1 (receiving transcranial direct current stimulation [tDCS] over the primary motor cortex), Experimental Group 2 (receiving simultaneous tDCS over the primary motor cortex and dorsolateral prefrontal cortex), and the sham group (receiving sham stimulation without an actual therapeutic effect). The random allocation sequence was generated using the Random Allocation Software by an independent individual who was not involved in the study.
For allocation concealment, a random code was assigned to each allocation, and the codes generated from the randomization sequence were placed separately in opaque, sealed envelopes. After each eligible participant entered the study, the envelopes were made available to the participant, who randomly selected one envelope. After opening the envelope, the code inside was matched with the randomization list, and the participant’s assigned group was determined. Thus, the participant’s selection of an envelope resulted in random allocation to one of the three groups, and group assignment could not be predicted or observed before the envelope was selected. The unit of randomization was the individual participant, and no block, stratified, or cluster randomization was used, Blinding description: Outcome assessors and participants were blinded to the type of intervention administered. Prior to the commencement of the study, to ensure allocation concealment, the codes generated from the random allocation sequence by an independent individual who was not involved in the study, using the Random Allocation Software, were placed separately in opaque, sealed envelopes. After each eligible participant entered the study, the participant randomly selected one of the envelopes. After opening the envelope, the code inside was matched with the randomization list, and the participant’s assigned group was determined. Thus, group allocation could not be observed or predicted by the participant or the outcome assessor before the envelope was selected and opened.
The interventions across the study groups were similar in terms of administration procedure, number and duration of sessions, and conditions of stimulation, with the only difference being the stimulation site in the active intervention groups. In the sham group, sham stimulation was administered using the same procedure. Therefore, participants were unaware of the type of intervention they received and their group allocation. Since participants were also unaware of the type of intervention administered to the other groups, they could not determine which group they had been assigned to.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Patellofemoral Pain Syndrome.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Transcranial Direct Current Stimulation Over the Primary Motor Cortex Participants in this group received transcranial direct current stimulation (tDCS) targeting the primary motor cortex. The intervention was administered using a Nerostim2 device manufactured by Medina Teb Gostar, Tehran, Iran, at a current intensity of 2 mA for 20 minutes per session. A total of 6 sessions were conducted, with 3 sessions per week over a period of 2 weeks. The international 10–20 brain mapping system and a dedicated electroencephalography cap were used to determine the precise electrode placement. Sponge electrodes soaked in saline solution were placed over the pre-marked areas. In participants with predominant symptoms in the right knee, the 4 × 5 cm anode was placed over the C3 location, whereas in participants with predominant symptoms in the left knee, the anode was placed over the C4 location. The 4 × 9 cm cathode was placed over the upper region of the contralateral orbit. Intervention 2: Intervention group: Simultaneous Transcranial Direct Current Stimulation Over the Primary Motor Cortex and Dorsolateral Prefrontal Cortex  Participants in this group received transcranial direct current stimulation (tDCS) targeting the primary motor cortex and dorsolateral prefrontal cortex simultaneously. The intervention was administered using a Nerostim2 device manufactured by Medina Teb Gostar, Tehran, Iran, at a current intensity of 2 mA for 20 minutes per session. The intervention consisted of a total of 6 sessions, with 3 sessions per week over a period of 2 weeks. The international 10–20 brain mapping system and a dedicated electroencephalography cap were used to determine the electrode placement. Sponge electrodes soaked in saline solution were placed over the marked areas. In this group, two 4 × 5 cm anodes were placed at the F3 and Cz locations. Two 4 × 9 cm cathodes were placed at AF8 and between AFz and FPz, respectively. Intervention 3: Control group: Sham Transcranial Direct Current Stimulation Participants in the control group received sham transcranial direct current stimulation (sham tDCS). The intervention was administered using a Nerostim2 device manufactured by Medina Teb Gostar, Tehran, Iran. To maintain conditions comparable to those of the intervention groups, participants underwent a total of 6 stimulation sessions, with 3 sessions per week over a period of 2 weeks. Each session lasted 20 minutes.The international 10–20 brain mapping system and a dedicated electroencephalography cap were used to determine the electrode placement. Sponge electrodes soaked in saline solution were placed over the designated areas. In the control group, the electrode placement procedure and session conditions were similar to those of the intervention groups. However, in the sham stimulation condition, the electrical current was gradually increased over a period of 30 seconds to mimic the sensation associated with anodal stimulation, after which the current was discontinued and returned to the initial state. Thus, no effective electrical stimulation was delivered to the target areas.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is To protect the confidentiality and privacy of participants’ information and due to restrictions on sharing individual-level data, the raw and individual participant data will not be made publicly available. The overall study results will be reported in an aggregated form, without any possibility of identifying individual participants.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Morvarid Ahmadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Second Taleghani Street, Arabi Intersection, right-hand side, the first cream-colored apartment building, first floor.</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4818959820</zip>
        <telephone>+98 11 3328 5108</telephone>
        <email>ahmadimorvarid177@gmail.com</email>
        <affiliation>Razi University, Kermanshah, Iran</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Farzaneh Gandomi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Razi University, University Street, Taq-e Bostan, Kermanshah, Iran</address>
        <city>Kermanshah</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6714414971</zip>
        <telephone>+98 83 3427 7605</telephone>
        <email>gandomi777@gmail.com</email>
        <affiliation>Razi University, Kermanshah</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Sex: Female
Age range: 18–35 years
The presence of knee valgus, as assessed by the Forward Step-Down Test
Unilateral knee pain
A minimum pain score of 3 on the Visual Analog Scale (VAS)
Anterior knee pain elicited during at least three of the following: prolonged sitting, stair ascent or descent, squatting, palpation of the patellar facets, bilateral squat, or a positive Clarke's test</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>35 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>History of knee injury or surgery involving the ligaments, menisci, or other knee structures.
Participants with knee pathologies such as knee osteoarthritis, patellar tendinopathy, meniscal lesions, osteochondral lesions, or ligament injuries.
Traumatic or recurrent patellar dislocation
Use of nonsteroidal anti-inflammatory drugs (NSAIDs) within the past week
Pregnancy
Psychiatric disorders
Previous treatment within the past 6 months</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Transcranial Direct Current Stimulation Over the Primary Motor Cortex Participants in this group received transcranial direct current stimulation (tDCS) targeting the primary motor cortex. The intervention was administered using a Nerostim2 device manufactured by Medina Teb Gostar, Tehran, Iran, at a current intensity of 2 mA for 20 minutes per session. A total of 6 sessions were conducted, with 3 sessions per week over a period of 2 weeks. The international 10–20 brain mapping system and a dedicated electroencephalography cap were used to determine the precise electrode placement. Sponge electrodes soaked in saline solution were placed over the pre-marked areas. In participants with predominant symptoms in the right knee, the 4 × 5 cm anode was placed over the C3 location, whereas in participants with predominant symptoms in the left knee, the anode was placed over the C4 location. The 4 × 9 cm cathode was placed over the upper region of the contralateral orbit.</i_keyword>
      <i_keyword>Intervention group: Simultaneous Transcranial Direct Current Stimulation Over the Primary Motor Cortex and Dorsolateral Prefrontal Cortex  Participants in this group received transcranial direct current stimulation (tDCS) targeting the primary motor cortex and dorsolateral prefrontal cortex simultaneously. The intervention was administered using a Nerostim2 device manufactured by Medina Teb Gostar, Tehran, Iran, at a current intensity of 2 mA for 20 minutes per session. The intervention consisted of a total of 6 sessions, with 3 sessions per week over a period of 2 weeks. The international 10–20 brain mapping system and a dedicated electroencephalography cap were used to determine the electrode placement. Sponge electrodes soaked in saline solution were placed over the marked areas. In this group, two 4 × 5 cm anodes were placed at the F3 and Cz locations. Two 4 × 9 cm cathodes were placed at AF8 and between AFz and FPz, respectively.</i_keyword>
      <i_keyword>Control group: Sham Transcranial Direct Current Stimulation Participants in the control group received sham transcranial direct current stimulation (sham tDCS). The intervention was administered using a Nerostim2 device manufactured by Medina Teb Gostar, Tehran, Iran. To maintain conditions comparable to those of the intervention groups, participants underwent a total of 6 stimulation sessions, with 3 sessions per week over a period of 2 weeks. Each session lasted 20 minutes.The international 10–20 brain mapping system and a dedicated electroencephalography cap were used to determine the electrode placement. Sponge electrodes soaked in saline solution were placed over the designated areas. In the control group, the electrode placement procedure and session conditions were similar to those of the intervention groups. However, in the sham stimulation condition, the electrical current was gradually increased over a period of 30 seconds to mimic the sensation associated with anodal stimulation, after which the current was discontinued and returned to the initial state. Thus, no effective electrical stimulation was delivered to the target areas.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain intensity. Timepoint: Before the intervention (pre-intervention) and after completion of the intervention (post-intervention). Method of measurement: Pain intensity will be measured using the Visual Analog Scale (VAS).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Static balance. Timepoint: Before the intervention (pre-intervention) and after completion of the intervention (post-intervention). Method of measurement: Static balance will be assessed using the TECNOBODY Prokin 252 balance system (Italy), located at the Exercise Physiology Laboratory, Faculty of Sport Sciences, Razi University.</sec_outcome>
      <sec_outcome>Dynamic balance. Timepoint: Before the intervention (pre-intervention) and after completion of the intervention (post-intervention). Method of measurement: Dynamic balance will be assessed using the Y-Balance Test (YBT).</sec_outcome>
      <sec_outcome>Forward Step-Down Test score. Timepoint: Before the intervention (pre-intervention) and after completion of the intervention (post-intervention). Method of measurement: The Forward Step-Down Test score will be assessed using the Forward Step-Down Test. During the test, participants will stand on a 20-cm step with their arms crossed over their chest. They will then be instructed to step forward toward the floor while maintaining balance on the weight-bearing limb. After the heel of the non-weight-bearing foot makes initial contact with the floor, they will return to the starting position.</sec_outcome>
      <sec_outcome>Motor function. Timepoint: Before the intervention (pre-intervention) and after completion of the intervention (post-intervention). Method of measurement: Motor function will be assessed using the Anterior Knee Pain Scale (AKPS), also known as the Kujala Questionnaire. This questionnaire evaluates patients' self-reported symptoms and functional limitations related to patellofemoral pain syndrome. It consists of 13 items assessing knee function during daily activities.</sec_outcome>
      <sec_outcome>Quadriceps muscle strength. Timepoint: Before the intervention (pre-intervention) and after completion of the intervention (post-intervention). Method of measurement: Quadriceps muscle strength will be assessed using a hand-held dynamometer.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Razi University, Kermanshah</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-07-01</approval_date>
        <contact_name>Research Ethics Committee of Razi University, Kermanshah</contact_name>
        <contact_address>Faculty of Sport Sciences, Razi University Campus, Baghe Abrisham, Kermanshah, Iran Kermanshah Kermanshah Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
